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Schizophrenia is associated with deficits in theory of mind (ToM) (i.e., the ability to infer the mental states of others) and
cognition.Associations have often been reported between cognition andToM, andToMmediates the relationship between impaired
cognition and impaired functioning in schizophrenia. Given that cognitive deficits could act as a limiting factor for ToM, this study
investigated whether a cognitive remediation therapy (CRT) that targets nonsocial cognition and metacognition could improve
ToM in schizophrenia. Four men with schizophrenia received CRT. Assessments of ToM, cognition, and metacognition were
conducted at baseline and posttreatment as well as three months and 1 year later. Two patients reached a significant improvement
in ToM immediately after treatment whereas at three months after treatment all four cases reached a significant improvement,
which was maintained through 1 year after treatment for all three cases that remained in the study. Improvements in ToM were
accompanied by significant improvements in the most severely impaired cognitive functions at baseline or by improvements in
metacognition. This study establishes that a CRT program that does not explicitly target social abilities can improve ToM.
1. Introduction
In schizophrenia, cognitive deficits are recognized as a core
feature of the disorder [1–3], with 80% of patients exhibiting
deficits in at least one cognitive domain [1, 4]. These deficits
do not typically resolve following antipsychotic treatments [1,
2]. The impact of these deficits on interpersonal and occupa-
tional functioning is well-established [5, 6], leading to major
efforts to further understand and treat these barriers to func-
tional recovery. In this paper, we refer to cognition as includ-
ing all nonsocial cognitive functions such asmemory or exec-
utive functions. Along with cognitive deficits, patients with
schizophrenia also present with social cognitive deficits [3].
Social cognition refers to the mental processes underlying
social interactions, including the abilities involved in per-
ceiving and interpreting social information in order to guide
social interactions [7].
Among all cognitive and social cognitive functions, the-
ory of mind (ToM) is most strongly associated with function-
ing in schizophrenia [5, 8–11] and is therefore an important
treatment target. ToM can be defined as the ability to repre-
sent and infer the mental states of other people such as
their intentions, emotions, or beliefs [7–9]. Even though ToM
judgments are by definition social judgments, several nonso-
cial cognitive functions likely contribute to making correct
inferences about other people’s mental states. In real life,
a poor memory could, for instance, make it harder to use
relevant cues from previous encounters with the same person
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[12]. In line with this idea, several studies have reported signi-
ficant associations betweenToMand a range of cognitive abil-
ities, including verbal memory, speed of processing, verbal
fluency, cognitive flexibility, inhibition, and reasoning [13–
21]. However, it remains unclear if one or a few cognitive
functions are more strongly associated with ToM than the
others.There is evidence that ToM acts as amediator between
cognition and different spheres of functioning such as social
[9, 22, 23] or occupational functioning [9, 23, 24], with
cognition influencing ToM, which in turn influences func-
tioning. Therefore, ToM abilities may in fact be more proxi-
mal to functioning than cognitive abilities. Given that ToM
is largely impaired in schizophrenia [3, 25–27], it is recog-
nized as an important treatment target to promote better
functioning in these patients.
Patients with schizophrenia often also present with meta-
cognitive impairments, including difficulties in estimating
the difficulty of a task (metacognitive knowledge) [28–30],
monitoring their performance during a task, or regulating
their cognition using efficient strategies (metacognitive reg-
ulation) [30]. Metacognitive skills are thought to contribute
to ToM, for instance, by enabling the flexibility required to
“shift back and forth from one’s own perspective to the valid
and differing perspectives of others” ([31], page 387). The
improvement of metacognitive abilities could thus be useful
for cognitive and social cognitive functioning.
Given the association between cognition and ToM abil-
ities [13–21] and between metacognition and ToM [31–33],
we could expect that addressing cognition andmetacognition
with a cognitive remediation therapy (CRT) could help
improve ToM abilities in patients with schizophrenia. CRT
is defined as a “behavioral training-based intervention that
aims to improve cognitive processes with the goal of durabil-
ity and generalization” [34]. Multiple CRT programs target-
ing various cognitive domains and using different method-
ology have been tested, revealing positive effects on cognitive
performance (reviewed in [34, 35]). Other CRTprograms tar-
geting social cognition have led to improved social cognition
performance (reviewed in [36]). However, despite the rec-
ognized relationship between cognition and ToM, no study
has yet investigated if a CRT targeting only cognition and
metacognition can also improve ToM performance. Further-
more, few studies have yet considered the cognitive profile
at baseline (i.e., having a deficit in cognition or ToM) as an
inclusion criterion. This in an important question given that
cognitive deficits could act as a limiting factor for ToM.
The aim of this study was to investigate the effect of a
CRT program (Computerized Interactive Remediation of
Cognition Training for Schizophrenia; CIRCuiTS) that tar-
gets cognitive functions and metacognitive skills on ToM
abilities in patients with schizophrenia. CIRCuiTS relies on
a drill and strategy approach and puts a strong focus on the
development of metacognitive skills and cognitive functions
using nonemotive material. In addition, we also explored the
changes in cognitive and metacognitive functions as well as
clinical symptoms and global functioning following the CRT.
We hypothesized that developing cognitive and metacogni-
tive abilities with CIRCuiTS would lead to improvements in
ToM.
2. Materials and Methods
2.1. Context. This multiple case study was conducted in
parallel with a previous study [37] that assessed the feasibility
of CIRCuiTS with young adults with schizophrenia. Four
patients with ToM deficits at baseline were included in the
present study, including two patients (Cases A and B) who
were included in our previously published feasibility study
(resp., designated as Cases A and C in the previous report
[37]). ToM performance was assessed as part of the same
study protocol, but these results were not previously pub-
lished. None of the participants presented with a current
developmental disorder that could have affected the per-
formance, such as autism or attention deficit hyperactivity
disorder.
2.2. Participants. All four participants had (1) a confirmed
DSM-IV diagnosis of schizophrenia; (2) a duration of illness
that did not exceed 10 years; (3) a clinical status that permitted
reliable cognitive assessment (i.e., the patient did not present
with acute psychotic symptoms that may affect the neu-
ropsychological assessment and their psychiatrist considered
that the collaboration and the medication were adequate for
the patient); (4) cognitive difficulties defined as a perfor-
mance equal to or below the 16th percentile either on the Rey
Complex Figure Test [38] or on the California Verbal Learn-
ing Test-II [39]; and (5) a ToM deficit defined as a perfor-
mance equal or below the 16th percentile on the Combined
Stories Task (COST) [8].
Exclusion criteria for the study were (1) brain and meta-
bolic disorders known to cause neuropsychological impair-
ments; (2) substance dependence in the last six months; and
(3) intellectual quotient (IQ) below 70 based on theWechsler
Adult Intelligence Scale third edition [40].
This study was approved by the ethics committee of
the Centre de Recherche de l’Institut Universitaire en Sante´
Mentale de Que´bec in Que´bec, Canada, and all participants
provided informed written consent.
2.3. Procedure. Baseline assessments included a ToM task
and a battery of cognitive and metacognitive tasks, admin-
istered by a research assistant, as well as measures of clinical
symptoms and global functioning, which were completed by
the treating psychiatrist. Following baseline assessment, CRT
was provided with the program CIRCuiTS, for a total of 40
sessions of approximately one hour each, at least three days
per week (mean duration = 17.4 weeks, or about 4 months).
The same assessment battery used at baseline was again
administered after the end of the treatment. Furthermore,
two follow-up assessments were conducted; the first one was
conducted three months after the end of the treatment (and
hence about 7 months after baseline assessment) and the
second one was conducted 1 year after the end of the treat-
ment (hence about 1 year and 4 months).
2.4. Material
2.4.1. ToMAssessment. ToMwas assessedwith theCombined
Stories Task (COST) [8], which requires participants to read
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short stories out loud and to answer one or two questions that
require taking into account the characters’ mental states (i.e.,
their intentions, beliefs, or emotions), for a total of 26 second-
order ToM questions. Answers are rated as 0, 1, or 2 points
for a total of 52 points. Participants are encouraged to refer
back to the written story to answer the questions if they need,
which is done to minimize the impact of potential difficulties
in being attentive to the text or in remembering the story.
Previous studies documented the excellent validity [8] and
test-retest reliability [41] of the COST.
2.4.2. Neuropsychological Assessment. The Wechsler Adult
Intelligence Scale third edition was used to provide a full
assessment of IQ (WAIS-III; [40]). The cognitive battery
included tests assessing different functions addressed by
CIRCuiTS: the digit span subtest (total) from the WAIS-III
[40] for verbal working memory and the spatial span (total)
[42] for visual working memory. Episodic memory (verbal
and visual) was assessed using the long-delay free recall of
the California Verbal Learning Test-II (CVLT-II) [39] and of
the Rey Complex Figure Test (RCFT) [38]. The Continuous
Performance Test-II (CPT-II) [43] was used to assess selective
attention (omission and commission) and sustained attention
(HRTBC andHSEBC). Cognitive flexibility was assessedwith
theWisconsin Card Sorting Test, 128 cards (WCST) (number
of categories completed) [44], the Stroop from the Delis-
Kaplan Executive Function System [45] condition 3 (total
time) was used to assess inhibition, the Tower of London
(TOL) (total problems solved correctly with the minimum
move) [46] was used to assess planning and organization, and
theMatrix reasoning subtest from theWAIS-III [40]was used
to assess reasoning. In the present study, a performance below
the 16th percentile was considered as a deficit.
2.4.3. Metacognitive Assessment. Metacognitive knowledge
(i.e., the knowledge about one’s own cognition) was assessed
with the Subjective Scale to Investigate Cognition in
Schizophrenia (SSTICS) [47]. This 21 items’ questionnaire
measures the patients’ understanding of his own cognitive
functioning [47].The SSTICS score needs to be interpreted in
the broader context of cognitive and behavioral performance.
While an increased score can be interpreted as an increased
impairment in these cognitive functions in daily life; it can
also be interpreted like a better metacognitive knowledge
about one’s own cognition in daily life. Metacognitive reg-
ulation (i.e., the ability to monitor and regulate one’s own
cognition) was assessed with the Behavior Rating Inventory
of Executive Function-Executive Global Index (BRIEF-A)
[48]. This index includes a self and an informant report (i.e.,
a first-degree family member in the current study), and both
were included in this protocol.TheBRIEF-A can be used as an
indicator of the patient awareness of his self-regulation [48].
A performance below the 16th percentile was considered as a
deficit.
2.4.4. Clinical Assessment. Global functioning was rated by
the treating psychiatrist using the Global Assessment of
Functioning (GAF) [49], which provides a single rating (0–
100) encompassing psychological, social, and occupational
functioning. Symptoms were rated with the Positive and
Negative Syndrome Scale (PANSS) [50], which allows a dis-
tinction between the following five symptom factors: positive,
negative, cognitive/disorganization, depression/anxiety, and
excitability/hostility [51].
2.4.5. CRTProgram. TheCRTprogramused in this studywas
the French Canadian adaptation of CIRCuiTS [37, 52, 53], an
individual computerized CRT program that aims to improve
cognition (attention, memory, and executive functions) and
metacognitive skills. CIRCuiTS aims to improve metacogni-
tive skills by promoting the constant monitoring, regulation,
and revision of performance during a task [28]. The devel-
opment of metacognitive skills is based on the metacogni-
tive model presented by Wykes and Reeder [30] in which
metacognitive knowledge and regulation are useful in the
transfer of cognitive skills in everyday life. Metacognitive
knowledge (knowledge about how cognitionworks in general
and one’s own cognition) can be helpful, for example, to
remembering a grocery list by knowing that classifying items
of a list in different categories facilitates remembering the
information. Similarly,metacognitive regulation (monitoring
and regulation of one’s own cognition) can, for example, be
used to adapt strategies in scheduling, such as “I struggle
to remember my appointment, so I will set an alarm on my
cellphone.”
This program trains cognitive functions using a drill/
practice and strategies method using 27 different tasks, each
with at least 12 levels of difficulty. A more complete descrip-
tion of the CRT program is provided elsewhere [37, 52].
2.5. Statistical Analyses. To investigate the effect of CIRCuiTS
on ToM abilities, Reliable Change Indices (RCIs) were calcu-
lated for ToM performance as assessed with the COST. RCIs
can be used to assess if the score of an individual has sta-
tistically changed after an intervention. They correspond to
the difference between two measures of the same individual,
divided by the standard error of the difference of the test
[54, 55]:
RCI = 𝑥2 − 𝑥1
√2 (𝑠1√1−𝑟
𝑥𝑥
)2
.
(1)
This figure is the equation published by Zahra and Hedge in
2010 based on Jacobson and Truax (1991) where 𝑥1 signifies
a participant pretest score and 𝑥2 signifies the posttest score
of the same participant. This score is divided by the Sdiff,
or standard error of the change score, that is the difference
between the scores (𝑥2 and 𝑥1), corrected for the reliability of
the instrument.The Sdiff represents the range of distribution
of change scores that could be expected if no interventionwas
done and is further explained in Jacobson & Truax (1991).
Briefly, 𝑠1 refers to the standard deviation of a normative
group at baseline and 𝑟𝑥𝑥 refers to the test-retest reliability
of the measure. Consequently, normative data were gathered
from a comparative sample of 𝑁 > 50 patients diagnosed
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with schizophrenia, and standard deviations were computed
for each variable in order to estimate the SE in the RCI
formula.
Here, an RCI was calculated (1) between baseline and
posttreatment, (2) between baseline and three months after
treatment, and (3) between baseline and 1 year after treat-
ment. RCIs are very conservative and can be interpreted
like 𝑍-change scores, hence being considered statistically
significant at 𝑝 < 0.05 if equal or superior to 1.64 (one-
tailed hypothesis) [54]. RCIs can be complemented by further
calculating the clinical significance of the change, that is,
whether the performance of a patient is in the range of the
healthy control population or of the schizophrenia popula-
tion after the treatment [56]. This is done by calculating a
cut-off considering the means and standard deviations from
a schizophrenia population and a healthy control population
[56]. With this equation, the clinical cut-off score for the
COST was 42.2/52. If the patient’s score surpasses the cut-off
point after the treatment, the change is considered clinically
significant [56].
In addition to ToM, RCIs were also calculated for all
cognitive and metacognitive measures, as well as for symp-
toms ratings and functioning ratings. To facilitate the inter-
pretation of the RCIs for cognitive measures for which a
decrease in scores reflects an improvement (CPT omission,
commission, HRTBC, HSEBC, Stroop, BRIEF, SSTICS, and
PANSS), these RCIs were multiplied by −1 such that positive
RCIs always reflected improvements. To assess the clinical
significance of changes in symptoms, changes of at least
25% on the PANSS total or subscale scores compared to
baseline were considered as clinically significant, as proposed
by Leucht [57]. For the GAF, a score above 59 was considered
as a remission state, as proposed by Bertelsen et al. [58].
3. Results: Case Presentation
3.1. Case A. Case A is a 26-year-old man who was diagnosed
with schizophrenia 7 years ago. At the time of testing, he was
taking clozapine and lamotrigine and presented with mild to
moderate positive (range of PANSS scores = 1–4; mean = 2.8)
and cognitive/disorganization symptoms (range of PANSS
scores = 1–5; mean = 2.8). He presented moderate difficulties
in global functioning (GAF = 42). His symptom ratings at
each time point are presented in the Supplementary Material
(see Table S1 in Supplementary Material available online at
https://doi.org/10.1155/2017/7203871). He completed 12 years
of education and was working part-time and going to school
full-time. His IQ at baseline was 78.
At baseline, Case A showed a severe ToM deficit, with a
performance below the 1st percentile. Case A also showed
cognitive deficits for visual and verbal episodic memory
and cognitive flexibility and also showed impairment for
the informant-rated metacognitive regulation. The scores
and percentiles at each time point are presented in the
Supplementary Material (Table S2). The evaluator reported
that Case A did not seem aware of his cognitive deficits at the
baseline. Case A completed 40 CRT sessions.
3.1.1. Changes in ToM Performance. As presented in Fig-
ure 1(a), Case A showed an increase in ToM performance
from baseline to posttreatment that did not reach statistical
significance (RCI = 1.26). His performance further increased,
and the improvement reached significance at three months
after treatment (RCI = 3.28) and remained significant 1 year
after treatment (RCI = 2.52). Regarding the clinical cut-off
score, despite the observed improvements, Case A’s ToM
performance was still considered as clinically impaired.
3.1.2. Concurrent Changes in Other Cognitive and Metacogni-
tiveMeasures. As shown in Figure 2, no concurrent improve-
ments in cognitive functions were observed following CRT.
The evaluator noted that Case A seemed less motivated and
that his attention was fluctuating throughout the posttreat-
ment and the follow-up assessments. However, significant
improvements were observed for metacognitive knowledge
and informant-reported metacognitive regulation. Thus,
Case A’s significant improvements in ToM were mostly
accompanied by improvements in his metacognitive abilities
(see details in the Supplementary Material, Table S2).
3.1.3. Concurrent Changes in Clinical Measures. Case A also
showed a statistically and clinically significant improvement
of his total clinical symptoms at posttreatment (RCI = 3.77),
including his positive (RCI = 3.77), negative (RCI = 2.90), and
depression/anxiety (RCI = 2.96) symptoms. The improve-
ment in negative symptoms was the only one to remain
clinically significant (though not statistically significant) at 3
months after treatment. There was a statistically significant
improvement in functioning (RCI = 2.58) which could
however be explained by the decrease of the severity of the
clinical symptoms. This improvement in global functioning
reached the remission criteria (59) at posttreatment, but these
improvements did not last at the follow-up assessments (see
details in the Supplementary Material, Table S1).
3.2. Case B. Case B is a 24-year-old man who was diagnosed
with schizophrenia 6 years ago. At the time of testing, he
was taking clozapine and presented with moderate to severe
positive symptoms (range of PANSS score = 3–6; mean = 5.3)
and moderate cognitive/disorganization symptoms (range of
PANSS score = 1–6; mean = 4.0). Moderate difficulties were
observed in his global functioning (GAF=38).The symptoms
ratings at each time point are presented in the Supplementary
Material (Table S3). He completed 7 years of education and
held a part-time job. His IQ at baseline was 73.
At baseline, Case B showed severe ToM impairments with
a performance below the 1st percentile and his most impor-
tant cognitive deficits were observed in episodic memory,
cognitive flexibility, verbal working memory, and selective
and sustained attention. The informant-rated metacognitive
regulation was also impaired. The scores and percentiles at
each time point are presented in the Supplementary Material
(Table S4). Despite important delusions, Case B was collab-
orative and motivated during baseline assessment according
to the evaluator. Case B completed 40 CRT sessions.
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Figure 1: Reliable change indices (RCIs) for theory of mind (ToM) performance on the COST for the four cases. Post = RCI from baseline to
posttreatment; 3 months = RCI from baseline to three months after treatment; 1 year = RCI from baseline to 1 year after treatment. The red
lines indicate the statistical threshold of 1.64.
3.2.1. Changes in ToM Performance. As presented in Fig-
ure 1(b), Case B showed a statistically significant improve-
ment in ToM performance from baseline to posttreatment
(RCI = 1.77). Case B again improved to reach his highest
RCI three months after treatment (RCI = 2.27). His RCI
also remained significant 1 year after treatment (RCI = 2.02).
Regarding the clinical cut-off score, he was still considered as
clinically impaired despite his improvements.
3.2.2. Concurrent Changes in Other Cognitive and Metacog-
nitive Measures. As shown in Figure 3, Case B benefited
from CRT, showing several cognitive improvements in areas
impaired at baseline. Indeed, significant RCIs for the post-
treatment and the two follow-up assessments are observed
in visual episodic memory, selective and sustained attention,
and planning/organization.
According to the evaluator, Case B was motivated at
posttreatment assessment but his delusions interfered with
the evaluation at three months and 1 year after treatment. No
significant improvements were observed for the metacogni-
tive measures (see details in Supplementary Material, Table
S4).
3.2.3. Concurrent Changes in Clinical Measures. Case B
showed significant statistical improvements on the PANSS
at posttreatment and for the two follow-ups for the total
(RCI = 2.94; 2.66; 2.66), positive (RCI = 3.01; 1.88; 1.88), and
cognitive/disorganization symptoms (RCI = 2.88; 2.88; 2.88).
Changes were clinically significant for positive symptoms
posttreatment. He showed statistically and clinically signif-
icant improvement of excitability/hostility symptoms three
months and 1 year after treatment (RCI = 1.86; 1.86). No
significant changes were observed for global functioning (see
details in the Supplementary Material, Table S3).
3.3. Case C. Case C is a 28-year-old man who was diagnosed
with schizophrenia 3 years ago. He was receiving clozapine
and presented withmoderate negative (range of PANSS score
= 2–5; mean = 3.1) and moderate cognitive/disorganization
symptoms (range of PANSS score = 1–4; mean = 2.2).
Moderate difficulties were identified in his global functioning
(GAF = 45). His symptom ratings at each time point are
presented in the Supplementary Material (Table S5). He
completed 11 years of education and was unemployed. His IQ
at baseline was 75.
At baseline, Case C showed a large ToM deficit with a
performance at the 8th percentile and his most important
cognitive deficits were observed for visual episodic memory,
selective attention, and executive functions (reasoning and
cognitive flexibility). The scores and percentiles at each time
point are presented in the Supplementary Material (Table
S6). Despite showing good collaboration during the baseline
assessment, CaseC’s attention seemed to fluctuate as reported
by the evaluator. Case C completed 39 CRT sessions.
3.3.1. Changes in ToM Performance. As presented in Fig-
ure 1(c), Case C showed a significant improvement in ToM
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Figure 2: Changes in ToMandneuropsychological andmetacognitive results for CaseA for each of the follow-up assessments (posttreatment,
3 months and 1 year after treatment). The color of the background indicates the severity of the deficit at baseline. A red background indicates
a severe impairment at baseline (≤6th percentile), a yellow background indicates an important impairment (7th to 16th percentile), and a
green background indicates a normal performance (≥17th percentile). The horizontal red line indicates the statistical RCI threshold of 1.64.
ToM = theory of mind; EM = episodic memory; WM = working memory; selec. att. = selective attention; com. = commission; sust. att. =
sustained attention; HSBEC = Hit Standard Error Block Change; HRTBC = Hit Reaction Time Block Change; om. = omission; reg. info =
Metacognitive Regulation Informant Report; reg. self = Metacognitive Regulation Self Report; knowledge = metacognitive knowledge.
performance from baseline to the end of the treatment (RCI
= 1.77) and three months after treatment (RCI = 2.27).
Case C did not consent to participate to the last assess-
ment 1 year after treatment. Case C had however already
surpassed the clinical cut-off score at posttreatment, meaning
that he was no longer considered as clinically impaired in
ToM.
3.3.2. Concurrent Changes in Other Cognitive and Metacog-
nitive Measures. As shown in Figure 4, Case C improved in
cognitive functions that were impaired at baseline. Indeed,
he showed a significant improvement in selective attention
at posttreatment and three months after treatment, as well
as a significant improvement in reasoning three months after
treatment. No significant improvement was observed for the
metacognitive measures (see details in the Supplementary
Material, Table S6). The evaluator reported his impression
that Case C exhibited a lack of motivation at posttreatment
and during the three months’ follow-up evaluation, which
could have impacted his results.
3.3.3. Concurrent Changes in Clinical Measures. The lack of
motivation of Case C was not explained by a change in his
clinical symptoms, which remained stable at posttreatment
Schizophrenia Research and Treatment 7
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Figure 3: Changes in ToMand neuropsychological andmetacognitive results for Case B for each of the follow-up assessments (posttreatment,
3 months and 1 year after treatment). The color of the background indicates the severity of the deficit at baseline. A red background indicates
a severe impairment at baseline (≤6th percentile), a yellow background indicates an important impairment (7th to 16th percentile), and a
green background indicates a normal performance (≥17th percentile). The horizontal red line indicates the statistical RCI threshold of 1.64.
ToM = theory of mind; EM = episodic memory; WM = working memory; selec. att. = selective attention; com. = commission; sust. att. =
sustained attention; HSBEC = Hit Standard Error Block Change; HRTBC = Hit Reaction Time Block Change; om. = omission; reg. info =
Metacognitive Regulation Informant Report; reg. self = Metacognitive Regulation Self Report; knowledge = metacognitive knowledge.
and during the three months’ follow-up. The GAF score of
Case C also remained stable (see details in the Supplementary
Material, Table S5).
3.4. Case D. Case D is a 33-year-old man who was diagnosed
with schizophrenia 2 years ago. At the time of testing,
he was receiving clozapine and presented with moderate
negative (range of PANSS score = 2–5; mean = 3.4) and
cognitive/disorganization symptoms (range of PANSS score =
1–5; mean = 3.2) as well asmild depression/anxiety symptoms
(range of PANSS score = 3-4; mean = 3.5). Moderate difficul-
ties were present in his global functioning (GAF = 48). The
ratings at each time point are presented in the Supplementary
Material (Table S7). He completed 16 years of education and
was unemployed. His IQ at baseline was 88.
At baseline, Case D showed a large ToM deficit with a
performance corresponding to the 16th percentile. The most
important cognitive deficits were observed for visual episodic
memory, sustained attention, cognitive flexibility, and inhibi-
tion. Self-rated metacognitive regulation and metacognitive
knowledge were also impaired. The scores and percentiles at
each time point are presented in the Supplementary Material
(Table S8). During baseline assessment, Case D showed good
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Figure 4: Changes in ToMandneuropsychological andmetacognitive results for CaseC for each of the follow-up assessments (posttreatment,
3 months and 1 year after treatment).The color of the background indicates the severity of the deficit at baseline. A red background indicates a
severe impairment at baseline (≤6th percentile), a yellow background indicates an important impairment (7th to 16th percentile), and a green
background indicates a normal performance (≥17th percentile). The horizontal red line indicates the statistical RCI threshold of 1.64. ToM =
theory of mind; EM = episodic memory; selec. att. = selective attention; om. = omission; com. = commission; WM = working memory; sust.
att. = sustained attention; HSBEC =Hit Standard Error Block Change; HRTBC =Hit Reaction Time Block Change; reg. info =Metacognitive
Regulation Informant Report; reg. self = Metacognitive Regulation Self Report; knowledge = metacognitive knowledge.
collaboration and motivation as reported by the evaluator.
Case D completed 38 CRT sessions.
3.4.1. Changes in ToM Performance. As presented in Fig-
ure 1(d), Case D showed a nonsignificant improvement in
ToM performance from baseline to the end of treatment
(RCI = 1.26) but then reached significant improvements three
months after treatment (RCI = 2.02) and 1 year after treatment
(RCI = 2.78). Regarding the clinical cut-off score, Case D
surpassed the criterion and was no longer considered as
clinically impaired at posttreatment and for the two follow-
up assessments.
3.4.2. Concurrent Changes in Other Cognitive and Metacogni-
tive Measures. As shown in Figure 5, Case D benefited from
CRTwith significant improvements in cognitive functioning,
including visual episodic memory, sustained attention, and
reasoning. No statistically significant improvements were
observed for the metacognitive measures (see details in the
SupplementaryMaterial, Table S8). During the posttreatment
and the follow-up assessments, the evaluator noted that Case
D was doing his best and was taking a long time to complete
the tasks properly.
3.4.3. Concurrent Changes in Clinical Measures. A statis-
tically and clinically significant change (RCI = 1.98) was
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Figure 5: Changes in ToMandneuropsychological andmetacognitive results for CaseD for each of the follow-up assessments (posttreatment,
3 months and 1 year after treatment). The color of the background indicates the severity of the deficit at baseline. A red background indicates
a severe impairment at baseline (≤6th percentile), a yellow background indicates an important impairment (7th to 16th percentile), and a
green background indicates a normal performance (≥17th percentile). The horizontal red line indicates the statistical RCI threshold of 1.64.
ToM = theory of mind; EM = episodic memory; sust. att. = sustained attention; HRTBC = Hit Reaction Time Block Change; WM = working
memory; HSBEC = Hit Standard Error Block Change; selec. att. = selective attention; com. = commission; om. = omission; knowledge =
metacognitive knowledge; reg. self = Metacognitive Regulation Self Report; reg. info = Metacognitive Regulation Informant Report.
observed for the depression/anxiety symptoms at posttreat-
ment. A clinically significant (but not statistically significant)
improvement was also observed for cognitive/disorganiza-
tion symptoms. Data were not available three months and 1
year after treatment. The GAF score of Case D stayed stable
at posttreatment (see details in the Supplementary Material,
Table S7).
4. Discussion
The aim of this study was to investigate whether a CRT pro-
gram (CIRCuiTS) that targets cognitive and metacognitive
functions can lead to improvements in ToM abilities in
patients with schizophrenia. Two out of four patients showed
a statistically significant ToM improvement at the end of the
treatment with CIRCuiTS, whereas at three months after
treatment, the improvement was significant for all four
patients. Data were also available at 1 year after treatment
for three patients, and even after this prolonged period, the
improvements remained significant for all three patients.
Overall, the results of this multiple case study show that it is
possible to improve ToM with a CRT program that targets
nonsocial functions. Furthermore, the effect of this therapy
on ToM lasted and even increased during the two follow-ups.
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Figure 6: Possible targets leading to ToM improvement.The colors indicate a significant improvement following CRT. In this figure, executive
functions include reasoning, cognitive flexibility, inhibition, and planning/organization. Episodic memory and working memory include
visual and verbal modalities. Selective attention includes omissions and commissions. Sustained attention includes the change in reaction
time.
4.1. CognitiveDifficulties as a Limiting Factor for ToMAbilities.
While the different processes that can be targeted to improve
ToM still need to be better delineated, several studies have
shown that ToM is an ability that relies onmultiple social and
nonsocial processes [9, 59–64]. As an example, to be able to
identify the intention of another person, it might be useful to
be attentive to social cues, tomaintain, recall, andmanipulate
different information in a flexible way and to inhibit some
responses. Associations between ToM and cognition are sup-
ported by several correlational studies that have shown signif-
icant relationship between ToM and various cognitive func-
tions such as verbal memory [13, 15, 20] or executive func-
tions [14, 19, 21]. Furthermore, Fanning et al. [13] reported
that ToM deficits often present along with cognitive deficits
in schizophrenia, such that 77% of patients that presented
with ToM deficits also showed cognitive impairments in that
study. The relationship between ToM and cognition is also
supported by the literature in social neurosciences. Several
studies have demonstrated that brain regions supporting
ToM tasks are not specific to social stimuli, as they are also
activated during nonsocial cognitive tasks [61, 64–66]. For
instance, the temporoparietal junction is activated during
attention reorientation tasks [64] and the medial prefrontal
cortex during higher-level information integration tasks
[61, 67]. However, despite multiple correlational studies, it
remains unclear if certain cognitive functions are more
crucial to ToM than others. While our results suggest that
the improvement of severe cognitive deficits can help to
improve ToM performance, this would need to be tested in a
larger group before drawing any conclusions about the larger
population of people with schizophrenia.
In the current study, the improvements in cognitive
functions along with improvements in ToM are in agreement
with the evidence in the literature that show associations
between cognition and ToM. Three cases (B, C, and D)
showed ToM improvements that were accompanied by sig-
nificant improvements in the cognitive functions that were
most severely impaired at baseline for each patient.The other
case (A) who was less severely impaired in cognition showed
significant improvement in metacognitive skills. Thus, our
observations are consistent with the suggestion by Schaafsma
et al. [59] that even if ToM tasks always involve social stimuli,
several cognitive functions can contribute to attributing the
correct mental states to another person. However, in order
to develop targeted and efficient CRT treatment, a better
understanding of the relationship between ToM, cognition,
and metacognition is necessary.
While the processes at play remain to be identified, the
current study supports our view that good cognitive func-
tioning is a basis for ToM, as illustrated in Figure 6. Strength-
ening this basis thus seems like a relevant target to improve
ToM and eventually functioning. For instance, to perform
adequately on ToM task such as the COST or other story-
based tasks, attentional and reasoning capacities are required,
and deficits in these functions could impact the performance
of the patient inToMby reducing his ability to direct attention
toward relevant information or by impairing the ability to
make sense of a situation. The current study also suggests
that metacognition can be useful to promote better ToM per-
formance, which we also illustrate in Figure 6. According to
the model of Wykes and Reeder [30], improvement of meta-
cognitive knowledge and regulation enables the patient to
be aware of his cognitive difficulties and to overcome these
difficulties by the monitoring of his performance and the
use of different strategies.The development of metacognition
is often used in treatment, given that admitting a problem
is recognized as an important first step to overcome it [32,
33]. On this topic, Passerieux et al. [33] suggested that, for
two patients with the same level of cognitive deficit, the
patient who has a better knowledge of his difficulties is in
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a better position to identify the challenges that it poses and
to take action to minimize the impact of his deficits [33].
Thus, based on the literature and our results, we suggest
that it is possible to improve ToM by targeting nonsocial
cognitive deficits that act as a limiting factor forToM.Also,we
suggest that metacognitive abilities could promote not only
cognitive functions, but also ToM performance. The current
study therefore adds to the literature, providing evidence for
the importance of cognition for ToM and the relevance of
addressing these deficits in treatment for ToM abilities.
4.2. CRT to Improve ToM in Schizophrenia. Our results
suggest that patients that present with multiple severe cog-
nitive deficits at baseline may benefit more from a CRT that
first targets general cognition, as these deficits could act as
limiting factors for their ToMperformance. In contrast, some
patients with less cognitive deficits may be more likely to
benefit from a CRT that directly targets their ToM abilities.
CRTs designed specifically to improve ToM abilities either
target one specific domain such as ToM [68, 69] or are broad-
based and allow the training of different component of social
cognition such as emotion recognition, attribution biases,
and ToM [70, 71]. Furthermore, metacognition is a common
target in CRT programs for social cognition to improve the
knowledge that the patient has about his own difficulties
[32, 33]. The development of metacognitive skills might be
a key factor to improve ToM deficits as observed for Case A
in the current study. However, except for Case A, who had
severe impairment in metacognition at baseline, the other
patients did not present withmajor deficits inmetacognition.
To improve their ToM abilities, patients are typically trained
to direct their attention toward relevant information and
interpret the meaning of different social situations presented
in comic strips or videos [33]. Several CRT programs for ToM
are based on strategy learning such as generating multiple
hypotheses regarding a social situation, searching and select-
ing relevant cues, and developing intentional reasoning (i.e.,
which character does what and inwhat intention?) [33].Thus,
the development of strategies embedded in CIRCuiTS could
be a key factor to improve ToM. CRT that target directly ToM
has shown efficacy in patients with schizophrenia [72] but
may not always be well-suited for all patients, or at least, not
as a first treatment target.
People with schizophrenia present with heterogeneous
cognitive profiles, with some patients showing impairments
in several areas and others presenting with only mild deficits
[1]. In order to enhance CRT efficacy, it is thus important to
determine the variables underlying each individual’s deficits
and tailor the CRT to suit these specific deficits [73]. All
patients start CRT with their own strengths and weaknesses,
and it is increasingly recognized that better outcome is
achieved when the treatment is personalized for a given
patient based on his cognitive profile [37, 73, 74]. In fact,
patients’ cognitive profiles before the start of CRT has been
reported as an important factor for treatment outcome in
several studies [73, 75–77].The specific improvements in cog-
nition or metacognition observed in our study highlight the
positive impact of the individualized approach of CIRCuiTS,
which sets personal goals before and during the therapy
to improve the most impaired cognitive functions for each
patient. Thus, applying the exact same protocol of treatment
to all patientsmight not be an optimal avenue to promote bet-
ter cognitive and ToM performance. In light of the literature
and the current results, it seems appropriate to acknowledge
the cognitive profile of the patient before CRT and to adapt
the treatment more specifically to his deficits, which may
sometimes mean choosing a nonsocial CRT to improve
ToM. In addition to the cognitive profile at baseline, several
other variables could potentially influence the effect of CRT
treatment, or how much treatment is required to observe an
effect [73]. In a literature review, Medalia and colleagues [73]
identified that factors that can promote a better response to
CRT treatments include younger age (critical window given
the higher neuroplasticity potential), shorter illness dura-
tion, increased number of CRT sessions, baseline cognitive
reserve, motivation, perception of competence, and a good
therapeutic alliance. In this study, patients who improved the
most in ToM at posttest had a lower IQ, but no clear pattern
was observed related to the age of the patients.
4.3. Detecting Cognitive Changes with Appropriate Measures.
ToM tasks with good psychometric properties are essential
to document changes in performance after CRT, but no
standardized tasks are currently available. A major initiative
[78] has recently investigated the psychometric properties of
several promising social cognitive tasks and found that, for
ToM, the Hinting task showed the strongest psychometric
properties among tasks that they examined. However, some
limitations such as ceiling effects or restricted ranges of per-
formance have been observed for theHinting task in previous
studies [79, 80], which could limit the capacity of this task to
detect changes after treatment.
The COST includes more items than the Hinting task and
previous studies have revealed normal distributions even in
healthy participants [8]. Previous studies have also shown
good psychometric properties for the COST, including good
convergent validity and internal consistency as well as excel-
lent interrater reliability [8]. Furthermore, high test-retest
reliability and an absence of a practice effect have been
demonstrated in a previous study [41, 81, 82]. Thus, patients’
improvements on the task in the current study are not likely
due to repeated assessment of the task, though future studies
will need to include a control groupwithout treatment to con-
trol for such effects. Finally, the results of this study show that
theCOST is sensitive to changes,meaning that it is possible to
detect a change in performance after a treatment. Therefore,
the COST seems like an advantageous measure to document
ToM improvements in future treatment studies.
In addition to taking the psychometric properties of the
measures into account, it is important to carefully interpret
the cognitive scores in the context of the CTR treatment
that the patient received. For instance, visual examination
of Figures 2, 3, 4, and 5 suggests that some patients in the
present study showed decreased cognitive performance after
CRT treatment, particularly for planning/organization and
low-order cognitive functions such as working memory and
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attention. The task used to assess planning/organization
involves solving a problem in a limited time.This is important
because, during CIRCuiTS, patients are instructed to take
their time and elaborate strategies when completing a task.
Therefore, as proposed by Cellard et al. [83], a decrease in
performance in this type of task should be interpreted with
caution, as it could reflect a better use of strategies that impact
positively everyday functioning. For low-order cognitive
functions, decreases were mostly observed in patients for
whom attention and working memory were not impaired at
baseline whereas patients with severe impairment in these
two cognitive functions improved after the therapy. This
could reflect the personalized administration of CIRCuiTS in
which impaired functions are more intensively trained.
4.4. Limitations. The limitations of this study include that
RCIs are very conservative and could prevent the detection
of some clinical changes that could positively impact patient
functioning, particularly at posttreatment, where several of
the RCIs were close to the significance threshold. To address
this limit, the clinically significant changes in ToM were also
presented in the article, and the clinically significant changes
for the cognitive and metacognitive measures were high-
lighted in the Supplementary Material. A second limitation
is that it is not possible to perform statistical analyses of
covariance in a multiple case study and we could therefore
not directly test whether the improvements in ToM and in
cognitive/metacognitive functions covary. Third, we cannot
exclude the nonspecific effect of the treatment that could
result from the patient having regular contact with the thera-
pist, which could have helped improve his social skills. How-
ever, prior to CRT, these patients were routinelymeeting with
diverse clinicians. It would thus be surprising that meeting
with the therapist for the CRT would more importantly
impact ToM. Fourth, all patients were receiving clozapine,
a medication for refractory clinical symptoms. It is however
noteworthy that the psychiatrists who referred the four
patients included in the current study are very proactive
with the use of clozapine. While they respect the need for
other prior treatments, they initiate clozapine as soon as a
lack of response is detected. Patients had, however, generally
responded well to clozapine and were stable at the time of
the evaluation andCRT.This homogeneity of treatment could
represent an advantage, though we cannot exclude that it
might have interacted with the effect of the CRT. However,
previous studies revealed no evidence of an effect of clozapine
on cognition or ToM [84–87]. The inclusion of patients with
more important metacognitive deficits at baseline would also
be interesting to confirm the hypothesis that metacognition
is a relevant target to improve ToM.
4.5. Conclusion. The results of this multiple case study pro-
vided initial evidence that a CRT targeting only nonsocial
cognition and metacognition can significantly improve ToM
abilities in patients with schizophrenia. These ToM improve-
ments were mostly accompanied by improvements in the
cognitive functions that were severely impaired at baseline,
which for one case included metacognitive abilities. This is
the first study, to the best of our knowledge, that has tested the
effect of a nonsocial CRTonToM.Though these resultswould
certainly need to be replicated in a larger sample in order to
determine if they can be more generally observed, they add
to the literature by suggesting that cognitive deficits can act
as a limiting factor for ToM at least in some patients. A better
understanding of how good cognition and metacognition
can promote ToM will be helpful in the future to ensure
optimal treatment and to promote functional recovery in
schizophrenia.
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